The Psychiatry Research Center is
currently enrolling subjects for:
ADOLESCENT BONE STUDY
Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy (Thrasher Foundation)
PI: Sriram Ramaswamy, M.D.
We are looking for two groups of subjects:
- Volunteers who are taking Haldol, Risperdal, or Zyprexa for a study about how medications affect teenagers bone health.
- Healthy volunteers not taking any antipsychotic medications
Eligibility criteria:
- Be 10-17 years old
- Be willing and able to come for 2 visits
Contact Coordinator: Angie at 402-345-8828 x24
--------------------------------
A Comparison of Bone Mineral Density Changes During Treatment With Risperidone or Aripiprazole in Adolescents (Bristol-Myers Squibb Company)
PI: Sriram Ramaswamy, M.D.
We are looking for three groups of subjects:
- Volunteers who are taking either Abilify for at least 1 year
- Volunteers who are taking Risperdal for at least 1 year
- Healthy volunteers not taking any antipsychotic medications
Eligibility criteria:
- Be 10-17 years old
- Be willing and able to come for 2 visits
Contact Coordinator: Angie at 402-345-8828 x24
-------------------------------
BIPOLAR DISORDERS
ADULT
Open Label Prophylaxis Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) Combination for Rapid Cycling Bipolar Disorder (Shire)
PI; Sriram Ramaswamy, M.D.
Have you been diagnosed with Bipolar Disorder and have rapid and accelerated mood swings? If so, you may be eligible to participate in a research study.
To be eligible you must:
- Be at least 19 years old
- Be currently taking Lithium for at least 6 months
- Not be diagnosed with Schizophrenia
- Not be addicted to drugs or alcohol for the past 30 days
- Be able to attend 19 visits during a 6-month period
Contact coordinator: Angie at 345-8828 x24
---------------------------------
A Phase 3, Randomized, 6-month, Double-Blind Trial in Subjects with Bipolar I Disorder to Evaluate the Continued Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer (vs Placebo Plus a Mood Stabilizer) Following a Minimum of 2 Months of Response to Open-Label Treatment with Both Agents (Pfizer A1281137)
PI: Shashi Bhatia, M.D.
If you are 19 years of age or older and you have been diagnosed with Bipolar Disorder, you may be able to participate in a new clinical research study of an investigational drug being studied for long-term use to see if it improves the condition of persons afflicted with this disorder.
Contact Coordinator: Angie at 345-8828 x24
-------------------------------
ADOLESCENTS
Four-Week, Double-Blind, Placebo-Controlled Phase III Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of Flexible Doses of Oral Ziprasidone in Children and Adolescents with Bipolar I Disorder (Manic or Mixed) (Pfizer A1281132)
PI: Shashi Bhatia, M.D.
Does your child have problems concentrating or is angry and irritable? Doesn’t feel like they fit in? Is unhappy? Does your child have bipolar disorder? If so, your child may be eligible to participate in a study.
To be eligible, your child:
- Must be 10-17 years old
- Must be diagnosed with or having symptoms of bipolar disorder
- Have extreme shifts in mood, energy & behavior
- Be irritable and/or depressed
- Be willing and able to come to the clinic weekly for 6 weeks
Contact Coordinator Megan at 345-8828 x21
-------------------------------
DEPRESSION
ADOLESCENTS
A Double-Blind Flexible Dose Study of Escitalopram in Pediatric Patients with Major Depressive Disorder
PI: Shashi Bhatia, M.D.
Does your teen experience depressed mood, loss of energy and worthlessness most of the day everyday and agree to experiencing these feelings?
The Creighton University Department of Psychiatry is currently conducting a research study for teen depression.
To be eligible, your child must be:
- Be between the ages of 12-17 years of age
- Be healthy
- Have no other psychiatric diagnosis
- Be able to attend weekly appointments for the first 6 weeks
Contact Coordinator Kim at 345-8828 x22
----------------------------
OBSESSIVE COMPULSIVE DISORDERS
ADULT
Acamprosate Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder (Forest Laboratories CMP-MD-14)
PI: Sriram Ramaswamy, M.D.
Do you experience symptoms such as persistent, unwelcome thoughts or images, or the urgent need to engage in certain rituals like repetitive hand washing, counting, checking, or cleaning even though you have been treated with medications?
To be eligible, you must also:
- Be at least 19 years old
- Be willing and able to come to the clinic weekly for 14 weeks
Contact Coordinator Angie at 345-8828 x24
------------------------------------------------------------
SCHIZOPHRENIA
ADULT
Relapse Prevention: Long-Acting Atypical Antipsychotics (NIH 1 U01 MH070016-01A2)
PI: Daniel R. Wilson, M.D., Ph.D.
This is a multicenter, randomized, open, effectiveness trial for patients with schizophrenia and schizoaffective disorder whose clinicians are considering long-term treatment with a second-generation antipsychotic medication.
To be eligible, you must also:
- Must be 19-75 years of age
- Had an exacerbation of your illness within the last 6 months
Contact Coordinator Kim at 345-8828 x22
--------------------------------
Predicting Response to Risperidone Treatment through Identification of Early-Onset of Antipsychotic Drug Action in Schizophrenia (Eli Lill F1D-US-HGMN)
PI: William Marcil, M.D.
Have you been diagnosed with schizophrenia and recently needed hospitalization, outpatient crisis management, or short-term treatment in an emergency room? If so, you might quality to participate in a research study to see if the response to Risperdal® Risperidone at two weeks will show better improvement for the treatment of schizophrenia.
To be eligible, you must also:
- Be between the ages of 19 and 65
- Have needed more care in the last two weeks (i.e. crisis management, increased clinic visits, emergency room treatment, or hospitalization)
- Be able to take study medication as directed
- Be able to come to the Creighton University Psychiatry Research Center 9 times over a 13-week period
Contact Coordinator Kim at 345-8828 x22
-----------------------------------
ADOLESCENTS
Six Week, Double-Blind, Placebo Controlled, Phase III Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of Flexible Doses of Oral Ziprasidone in Adolescent Subjects with Schizophrenia (Pfizer A1281134)
PI: Shashi Bhatia, M.D.
Thousands of young people are diagnosed with schizophrenia, a devastating but manageable disorder. Creighton University Psychiatry Research Center is currently enrolling teenagers in a clinical research study evaluating an investigational drug for schizophrenia.
To be eligible, your child must:
- Be 13-17 years old
- Diagnosed with or having symptoms of schizophrenia such as:
- seeing or hearing things that are not real
- vivid and bizarre thoughts and ideas
- unusual speech that is disorganized
- lack of motivation and emotional expression
- Be accompanied by a parent or guardian at each study visit
Contact Coordinator Megan at 345-8828 x21
-------------------------------------------------
For research studies conducted in the Psychiatry Research Center, we offer a comprehensive psychiatric evaluation, laboratory workup, ECG, and study medications based on the guidelines of the study. In addition, we offer compensation for your time and travel to the Creighton University Psychiatric Research Center located at 3528 Dodge Street.
If you are interested in learning more about our research studies, please call the Psychiatry Research Center at 402-660-2903.
Thank you for your interest!
